ReviewJournal of diabetes science and technology2017
Oral Insulin Delivery in a Physiologic Context: Review.
Review in Journal of diabetes science and technology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus.Clinical pharmacology in drug development · 2020Trial
- Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open-Label, Placebo-Controlled, Crossover Study.Clinical and translational science · 2019Trial
- Re-engineering insulin for oral delivery: structural modifications, advanced formulation strategies, and future directions.Drug delivery · 2026Review
- Small Intestine-Targeted Long-Acting Oral Insulin Formulation Based on Engineered Milk Protein Nanoparticles.ACS applied bio materials · 2026Article
- Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers.Science advances · 2026Article
- Prospects for the convergence of polyphenols with pharmaceutical drugs in type 2 diabetes: Challenges, risks, and strategies.Pharmacological reviews · 2025Review
- Effectiveness of open-source Android artificial pancreas systems for glucose management in patients with type 1 diabetes: a real-world study.Therapeutic advances in endocrinology and metabolism · 2025Article
- Impact of structure and formulation changes on the function of insulin products.Frontiers in endocrinology · 2025Review
- Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia.Nature nanotechnology · 2024Article
- Recent advances in oral insulin delivery technologies.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- The Disulfide Bond-Mediated Cyclization of Oral Peptides.Current protein & peptide science · 2024Review
- Review
- Challenges and Opportunities in the Oral Delivery of Recombinant Biologics.Pharmaceutics · 2023Review
- Ligand-switchable nanoparticles resembling viral surface for sequential drug delivery and improved oral insulin therapy.Nature communications · 2022Article
- Oral delivery of proteins and peptides: Challenges, status quo and future perspectives.Acta pharmaceutica Sinica. B · 2021Review
- Insulin-Loaded Barium Salt Particles Facilitate Oral Delivery of Insulin in Diabetic Rats.Pharmaceutics · 2020Article
- "Oil-soluble" reversed lipid nanoparticles for oral insulin delivery.Journal of nanobiotechnology · 2020Article
- Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability.Nature biomedical engineering · 2020Article
- Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations.Journal of the Endocrine Society · 2019Article
- Ionic liquids for oral insulin delivery.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin remains indispensable to the treatment of diabetes, but its availability in injectable form only has hampered its timely and broader use. The development of an oral insulin remains an ultimate goal to both enhance ease of use, and to provide therapeutic advantages rooted in its direct delivery to the portal vein and liver. By mimicking the physiological path taken by pancreatic insulin, oral insulin is expected to have a distinct effect on the hepatic aspect of carbohydrate metabolism, hepatic insulin resistance, and, at the same time, avoid hyperinsulinemia and minimize the risk of hypoglycemia. With oral insulin approaching late stages of development, the goal of this review is to examine oral insulin in a physiological context and report on recent progress in its development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.